Heron Therapeutics Inc. Daily Stock Analysis

Daily Stock Analysis, HRTX, Heron Therapeutics Inc, priceseries

Heron Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
5.36
Close
5.17
High
5.57
Low
5.17
Previous Close
5.31
Daily Price Gain
-0.14
YTD High
10.40
YTD High Date
Jan 4, 2022
YTD Low
5.17
YTD Low Date
Mar 7, 2022
YTD Price Change
-4.77
YTD Gain
-47.99%
52 Week High
18.99
52 Week High Date
Apr 28, 2021
52 Week Low
5.17
52 Week Low Date
Mar 7, 2022
52 Week Price Change
-11.96
52 Week Gain
-69.82%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jul 13. 2017
14.90
Jul 27. 2017
16.50
10 Trading Days
10.71%
Link
LONG
Sep 25. 2017
15.45
Oct 9. 2017
16.45
10 Trading Days
6.49%
Link
LONG
Dec 18. 2017
17.00
Jan 30. 2018
22.84
28 Trading Days
34.34%
Link
LONG
Sep 9. 2019
18.42
Sep 19. 2019
20.26
8 Trading Days
9.99%
Link
LONG
Oct 23. 2019
19.24
Nov 6. 2019
20.81
10 Trading Days
8.17%
Link
LONG
Nov 15. 2019
21.58
Dec 12. 2019
25.56
18 Trading Days
18.46%
Link
LONG
Apr 6. 2020
12.78
Apr 23. 2020
14.40
12 Trading Days
12.70%
Link
LONG
May 15. 2020
15.12
Jun 11. 2020
18.63
18 Trading Days
23.22%
Link
LONG
Dec 21. 2020
19.46
Jan 5. 2021
20.57
9 Trading Days
5.72%
Link
LONG
Jun 7. 2021
13.88
Jun 18. 2021
15.09
9 Trading Days
8.69%
Link
LONG
Oct 27. 2021
10.82
Nov 10. 2021
11.51
10 Trading Days
6.35%
Link
Company Information
Stock Symbol
HRTX
Exchange
NasdaqCM
Company URL
http://www.herontx.com
Company Phone
6503662626
CEO
Barry D. Quart
Headquarters
California
Business Address
4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA 92121
Sector
Equity
Industry Category
Drugs
Industry Group
Drug Manufacturers - Major
CIK
0000818033
About

Heron Therapeutics, Inc. is a biotechnology company develops pharmaceutical products for patients suffering from cancer or pain. The company develops products by using its proprietary Biochronomer polymer based drug delivery technology. Its primary products are SUSTOL, HTX-019 and HTX-011. The company has additional clinical and preclinical-stage programs in the area of pain management, all of which utilize its bioerodible, injectable and implantable delivery systems. Heron Therapeutics was founded in February 1983 and is headquartered in Redwood City, CA

Description

Heron Therapeutics, Inc., a biotechnology company, develops products to address unmet medical needs using its proprietary Biochronomer polymer-based drug delivery platform in the United States. Its drug delivery platform is designed to enhance the therapeutic profile of injectable pharmaceuticals. The company's lead product candidate includes SUSTOL (granisetron injection, extended release), which is in Phase III clinical trial for the prevention of acute- and delayed-onset chemotherapy-induced nausea and vomiting. It is also developing HTX-011 that is in Phase I clinical trial for the management of post-operative pain; HTX-019, an injectable neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting; and HTX-003, a formulation of buprenorphine for the management of chronic pain and opioid addiction. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Redwood City, California.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading